The
new biotherapeutics section on the EDQM website summarises Ph. Eur. Commission
activities and achievements in this field. In addition to clarification of the
role of Ph. Eur. monographs in the biosimilars regulatory pathway, it describes
the recently concluded P4-BIO pilot phase and the ongoing pilot phase on monoclonal
antibodies (“MAB pilot phase”), explaining the strategy followed by the Ph.
Eur. when setting requirements for the quality of this important class of
biotherapeutics. It also describes various levels of flexibility integrated
into Ph. Eur. texts, including those introduced recently to address the
structural complexity, heterogeneity and compound diversity derived from different
manufacturing processes of complex biotherapeutics.
Pharmaceutical Microbiology Resources. Edited by Dr. Tim Sandle (established 2010)
Thursday, 20 September 2018
EDQM publishes a new section dedicated to biotherapeutics
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources